ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

PMN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ProMIS Neurosciences, Inc.NASDAQ: PMN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2026 stock-based compensation of $408.89K rose 92.9% year over year, behind the +71257.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +92.9% toward the trailing-twelve-month pace of +71257.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$408.89K— QoQ
Last fiscal yearDec 2025
$857.63K+3.9% YoY
LTMJun 2026
$857.38M+71257.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+92.9%——
1 year+3.9%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

Mixed currencies · from the cash flow

Latest · FY2025
857.63K USD
Year-over-year change
+3.9%

Stock-Based Compensation vs competitors

How PMN compares with its peers on the latest reported figures

  • PMN's LTM Jun 2026 stock-based compensation of $857.38M is the largest of the 4 companies compared; the peer median is $729.64K.
  • Its year-over-year change of +71257.3% is the highest of 3, against a peer median of +17.7%.
  • Over three fiscal years its annual growth of +9.4% compares with a peer median of -31.4%.
PMN Competitors Peer median
Stock-Based Compensation for PMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PMNProMIS Neurosciences, Inc.LTM Jun 2026$857.38M +71257.3%+9.4%—
ANLAdlai Nortye Ltd.LTM Jun 2024$1.94M ——29.9%
EDSAEdesa Biotech, Inc.LTM Mar 2026$729.64K +113.5%-31.4%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$125K -78.0%——
Peer median (excluding PMN) $729.64K+17.7%-31.4%29.9%

Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(9.4M)(24.27M)(13.21M)2.78M(39.72M)
Depreciation & Amortization46.46K15.07K21.16K00
Deferred Income Tax00000
Stock-Based Compensation0655.2K271.54K825.81K857.63K
Change in Working Capital(1.59M)7.26M2.94M(11.73M)10.75M
Accounts Receivables(17.57K)0000
Inventory00000
Accounts Payables(32.09K)3.6M4.96M(6.11M)805.95K
Other Working Capital(1.54M)3.66M(2.02M)(5.62M)9.94M
Other Non-Cash Items1.5M(6.55M)(868.56K)(19.06M)(5.59K)
Operating Cash Flow(9.44M)(22.89M)(10.84M)(27.18M)(28.12M)
Capital Expenditures(6.12K)(2.66K)000
Acquisitions (Net)99.7K0000
Purchases of Investments(33.56K)(41.67K)(32.36K)(33.05K)(33.75K)
Sales of Investments35.92K41.67K31.01K32.36K33.05K
Other Investing Activities00000
Investing Cash Flow95.93K(2.66K)(1.35K)(693)(702)
Debt Repayment00000
Common Stock Issued25.63M6.68M17.75M27.85M20.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities02.04M3.6K28.04K0
Financing Cash Flow25.63M8.73M17.75M27.88M20.94M
Effect of Forex Changes(114.46K)(707.96K)(181.43K)00
Net Change in Cash16.17M(14.87M)6.72M693.02K(7.17M)
Free Cash Flow(9.45M)(22.89M)(10.84M)(27.18M)(28.12M)

ProMIS Neurosciences, Inc.

NASDAQ:PMN

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.